Nurix Therapeutics to Host a Webcast and Conference Call to Discuss Data from the Ongoing Phase 1 Clinical Trial of NX-5948 Being Presented at the European Hematology Association Congress (EHA2024)

June 10, 2024

https://www.globenewswire.com/news-release/2024/06/10/2895879/0/en/Nurix-Therapeutics-to-Host-a-Webcast-and-Conference-Call-to-Discuss-Data-from-the-Ongoing-Phase-1-Clinical-Trial-of-NX-5948-Being-Presented-at-the-European-Hematology-Association-C.html

SAN FRANCISCO, June 10, 2024 (GLOBE NEWSWIRE) — Nurix Therapeutics, Inc. (Nasdaq:NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that the company will host a webcast and conference call at 9:00 a.m., ET, on Sunday, June 16, 2024, to discuss data from the ongoing Phase 1 clinical trial of NX-5948 that will be presented in an oral session at the European Hematology Association Congress in Madrid, Spain.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.